--- title: "April starts with a bang, the innovative drug concept collectively explodes, ChemPartner hits the 20% daily limit up" type: "News" locale: "en" url: "https://longbridge.com/en/news/281340367.md" description: "On April 1st, all three major A-share indices rose by more than 1%, with innovative drug concept stocks collectively increasing, and multiple stocks such as ChemPartner hitting the daily limit. The upcoming 2026 American Association for Cancer Research Annual Meeting has become a catalyst for market enthusiasm. Huayuan Securities pointed out that China's pharmaceutical industry has completed the transition from generics to innovation, with innovative drugs becoming a new engine for industry growth. Future investments should focus on innovative drug companies with global competitiveness and cutting-edge technology directions" datetime: "2026-04-01T09:29:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281340367.md) - [en](https://longbridge.com/en/news/281340367.md) - [zh-HK](https://longbridge.com/zh-HK/news/281340367.md) --- # April starts with a bang, the innovative drug concept collectively explodes, ChemPartner hits the 20% daily limit up On April 1st, all three major A-share indices rose by more than 1%, with the Sci-Tech Innovation 50 Index increasing by over 3%. In terms of sectors, the innovative drug concept celebrated collectively, with Guangsheng Tang, ChemPartner, and Eddie Pharmaceuticals all hitting the 20% daily limit up, while Jin Pharmaceutical achieved four consecutive limit ups. Several concept stocks, including Huiyu Pharmaceutical, Yifang Biotechnology, and Chengda Pharmaceuticals, also saw significant gains. On the news front, the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting has become the catalyst igniting enthusiasm in the sector. This year's AACR Annual Meeting will be held from April 17 to 22 in San Diego, California, USA. As one of the largest and most influential academic events in the field of oncology globally, the AACR Annual Meeting serves as an important barometer for the development of the global innovative drug industry. The conference gathers top scientists, clinical doctors, and industry leaders from around the world each year, focusing on cancer treatment and showcasing cutting-edge breakthrough research results. Huayuan Securities' research report believes that China's pharmaceutical industry has completed the momentum shift from imitation to innovation, with innovative drugs becoming a new engine for industry growth. Investment in 2026 should revolve around the dual main lines of "technology innovation leadership" and "performance and valuation recovery," with a focus on leading innovative drug companies with global competitiveness and strong overseas capabilities, while actively laying out in cutting-edge technology directions such as AI healthcare and brain-computer interfaces ### Related Stocks - [516060.CN](https://longbridge.com/en/quote/516060.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159835.CN](https://longbridge.com/en/quote/159835.CN.md) - [300149.CN](https://longbridge.com/en/quote/300149.CN.md) - [515120.CN](https://longbridge.com/en/quote/515120.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [AI Agent Isolation Model and Security Boundary from a System Perspective](https://longbridge.com/en/news/287033210.md) - [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md) - [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md)